TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

13 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Heart / cardiovascular diseaseDementia / Alzheimer's

    📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →

    PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.

    ✓ Study care freePhase 4Ages 75+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Obesity / overweightType 2 diabetesHeart / cardiovascular disease

    📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →

    Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 30–70Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →

    A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.

    ✓ Study care freePhase 4Ages 40–80Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Eczema / atopic dermatitis

    📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →

    24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Eczema / atopic dermatitis

    📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →

    Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

    ✓ Study care freePhase 4Ages 6–17Learn more →
  • Eczema / atopic dermatitis

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →